These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28255229)

  • 1. Biosimilars and the extrapolation of indications for inflammatory conditions.
    Tesser JR; Furst DE; Jacobs I
    Biologics; 2017; 11():5-11. PubMed ID: 28255229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
    Li E; Lobaina E
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical guide about biosimilar data for health care providers treating inflammatory diseases.
    Markenson J; Alvarez DF; Jacobs I; Kirchhoff C
    Biologics; 2017; 11():13-21. PubMed ID: 28280299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S; Hanauer S
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
    Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
    Melosky B; Reardon DA; Nixon AB; Subramanian J; Bair AH; Jacobs I
    Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Opportunities and challenges of extrapolation for biosimilars].
    Weise M; Wolff-Holz E
    Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
    Schiestl M; Zabransky M; Sörgel F
    Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: Extrapolation for oncology.
    Curigliano G; O'Connor DP; Rosenberg JA; Jacobs I
    Crit Rev Oncol Hematol; 2016 Aug; 104():131-7. PubMed ID: 27354233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars Have Arrived: Rituximab.
    Greenwald M; Tesser J; Sewell KL
    Arthritis; 2018; 2018():3762864. PubMed ID: 29765782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
    Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
    Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
    J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rise of oncology biosimilars: from process to promise.
    Verrill M; Declerck P; Loibl S; Lee J; Cortes J
    Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
    Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
    Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.